Medicare covers GLP-1 drugs for type 2 diabetes — Ozempic and Mounjaro are covered under Part D. Wegovy is now covered for patients with cardiovascular disease following the 2024 SELECT trial results. Weight loss alone is not a covered indication. The 2026 Part D out-of-pocket cap is $2,000.
Medicare covers GLP-1 drugs for type 2 diabetes — but coverage for weight loss alone remains limited in 2026. Ozempic (semaglutide) and Mounjaro (tirzepatide) are covered under Medicare Part D when prescribed for type 2 diabetes. Wegovy (semaglutide) received expanded Medicare coverage in 2024 for patients with cardiovascular disease risk, following an FDA label change — but is not covered for weight loss alone without a qualifying condition. Here is exactly what Medicare covers, what it does not, and how to minimize your out-of-pocket costs.
Last updated: May 2026 | Reviewed quarterly
Disclaimer: Medicare coverage policies change. This article reflects publicly available CMS guidance as of May 2026. Always verify your specific plan's formulary and coverage directly with Medicare or your Part D plan before filling a prescription. This is not medical advice.
| Drug | Brand | Generic | Covered for Diabetes | Covered for Weight Loss | Part D or Part B |
|---|---|---|---|---|---|
| Semaglutide injection | Ozempic | No | ✅ Yes (Part D) | ❌ No (without CVD) | Part D |
| Semaglutide injection | Wegovy | No | N/A | ✅ If CVD risk (Part D) | Part D |
| Tirzepatide injection | Mounjaro | No | ✅ Yes (Part D) | ❌ No (without diagnosis) | Part D |
| Tirzepatide injection | Zepbound | No | N/A | Limited (Part D) | Part D |
| Dulaglutide | Trulicity | No | ✅ Yes (Part D) | ❌ No | Part D |
| Liraglutide | Victoza | No | ✅ Yes (Part D) | ❌ No | Part D |
| Exenatide | Byetta | No | ✅ Yes (Part D) | ❌ No | Part D |
Medicare Part D covers GLP-1 medications when they are FDA-approved and prescribed for a covered indication. The key covered indications:
Covered under most Part D plans (2026):
Not covered under standard Part D:
Important 2026 update: The Inflation Reduction Act and subsequent CMS guidance created pathways for Part D plans to cover Wegovy for cardiovascular risk reduction. However, plan formulary coverage varies — not all Part D plans include Wegovy. Check your specific plan's formulary using Medicare's Plan Finder tool at medicare.gov.
Under the Inflation Reduction Act, Medicare Part D out-of-pocket costs are capped at $2,000 per year for all covered drugs starting in 2025. This is a significant change from prior years.
2026 Medicare Part D cost structure:
Estimated Part D costs for Ozempic and Wegovy:
Manufacturer savings programs: Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) offer savings cards — but most are not eligible for Medicare beneficiaries due to federal anti-kickback rules. Verify eligibility with your prescribing physician.
Partially — with conditions. Wegovy's coverage under Medicare expanded significantly following the 2024 SELECT clinical trial, which showed semaglutide reduced major cardiovascular events (heart attack, stroke) by 20% in obese patients with established cardiovascular disease.
Wegovy is now covered by Medicare Part D for patients who:
Wegovy is NOT covered if:
Bottom line: If you or a loved one has cardiovascular disease and obesity, ask your doctor whether Wegovy is appropriate — it is now coverable under Medicare Part D for that specific indication.
No — not for weight loss alone in 2026. Mounjaro is covered under Medicare Part D when prescribed for type 2 diabetes. Zepbound (the same tirzepatide at the same dose, branded specifically for weight loss) does not have the same cardiovascular outcome data as Wegovy and is not covered for obesity/weight loss under standard Medicare Part D as of May 2026.
Coverage path for Mounjaro/Zepbound:
Medicare Advantage plans (Part C) must cover at minimum what Original Medicare covers, but many Advantage plans include enhanced drug benefits. Some Medicare Advantage plans cover GLP-1 drugs for weight loss beyond the standard Part D rules — particularly plans in competitive markets.
Check with your Medicare Advantage plan directly:
Does Medicare cover Ozempic in 2026?
Yes — Medicare Part D covers Ozempic (semaglutide) when prescribed for type 2 diabetes. It is not covered solely for weight loss. Coverage and copay depend on your specific Part D plan's formulary.
Does Medicare cover Wegovy in 2026?
Medicare Part D covers Wegovy for patients with established cardiovascular disease (history of heart attack, stroke, or peripheral artery disease) and obesity, following the FDA's 2024 label update. It is not covered for weight loss without a cardiovascular disease diagnosis.
Does Medicare cover Mounjaro in 2026?
Medicare Part D covers Mounjaro (tirzepatide) for type 2 diabetes. Zepbound (tirzepatide for weight loss) is generally not covered for obesity without a qualifying diagnosis.
What is the Medicare out-of-pocket cap for drugs in 2026?
Under the Inflation Reduction Act, Medicare Part D out-of-pocket costs for covered drugs are capped at $2,000 per year starting in 2025. This significantly reduces the annual cost burden for beneficiaries on expensive medications like GLP-1 drugs.
Can I appeal if my Medicare plan denies coverage for a GLP-1 drug?
Yes. You have the right to appeal a coverage denial. Your doctor must submit a coverage exception request documenting medical necessity. Contact 1-800-MEDICARE or your SHIP counselor for help filing an appeal.
What if I cannot afford my GLP-1 drug on Medicare?
Contact your State Pharmaceutical Assistance Program (SPAP), the Medicare Extra Help program (Low-Income Subsidy), or your state Medicaid program. Extra Help can significantly reduce Part D premiums and copays for qualifying low-income beneficiaries.
Is there a generic GLP-1 available on Medicare?
Not as of May 2026. All major GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity) are brand-name only. Generic semaglutide is not yet FDA-approved — patents on the major GLP-1 drugs extend through the late 2020s and early 2030s.
Does Medicare Part B cover GLP-1 injections?
No. GLP-1 drugs are self-administered injections covered under Part D (prescription drug coverage), not Part B (which covers physician-administered drugs). Make sure you have Part D coverage — either standalone or through a Medicare Advantage plan.
Disclaimer: Medicare coverage rules, formulary policies, and drug pricing change frequently. The information in this article reflects publicly available CMS guidelines and formulary data as of May 2026. Always verify your specific plan's coverage directly with Medicare or a licensed Medicare insurance counselor before making healthcare decisions. This article does not constitute medical or legal advice. Consult your healthcare provider for medical guidance.
Author: SeniorSimple Editorial Team — Medicare researchers and benefits specialists dedicated to helping seniors understand their coverage options clearly and simply.
Estimate your Medicare costs and compare plan options
Affects IRMAA surcharges for higher earners
Enter your information to see Medicare cost estimates
The best Medicare Part D drug plans of 2026 reviewed by cost and coverage: AARP MedicareRx Preferred earns the highest 4.5-star CMS rating with the broadest formulary, SilverScript Plus offers the best value for generic users, and Humana Premier Rx leads on premium cost at $9.70/month. In 2026, the new $2,000 out-of-pocket cap makes plan selection more important than ever.
Claiming Social Security at 62 permanently reduces your benefit by 25–30%. Waiting to 70 increases it by 24–32% above your Full Retirement Age benefit. The break-even age where waiting pays off is typically 78–83 depending on comparison. This guide walks through every scenario with real numbers.
Medicare Supplement Plan G vs Plan N in 2026: Plan G is best for frequent healthcare users; Plan N saves $50-$150/month for healthy seniors. Side-by-side coverage comparison with break-even analysis.
Get expert insights and practical advice delivered to your inbox weekly.
Join 50,000+ seniors making informed retirement decisions.
